Articles tagged with Lung Cancer
A study of nearly 15,000 adults with non–small cell lung cancer found that Medicaid expansion decreased postoperative mortality within 30 and 90 days after hospital discharge. This suggests that expanded Medicaid coverage may improve cancer outcomes and access to care for this population.
Researchers found a combination treatment involving high doses of radiation and chemotherapy to be safe and effective in treating locally advanced non-small cell lung cancer. The treatment, which includes an adaptive boost plan, showed promising results in improving progression-free survival and reducing toxic side effects.
Researchers developed nanosensors that can be inhaled and detected in urine, offering a potential alternative to CT scans for early lung cancer detection. The diagnostic system shows high specificity and sensitivity in detecting stage 1 or 2 lung tumors.
A phase III study found that selpercatinib significantly improves cancer progression-free survival in patients with NSCLC and RET gene translocations. The therapy also demonstrated efficacy in treating intracranial lesions, a common challenge in advanced NSCLC.
A risk model based on routine blood work can identify cancer patients who are more likely to benefit from immune checkpoint inhibitors, increasing treatment efficacy and cost-effectiveness. The study found that patients in the low-risk group had a higher response rate and longer overall survival compared to those in the high-risk group.
A survey of low-income adults showed a significant decrease in food insecurity, from 20.6% in 2019 to 15.5% in 2021. The findings highlight the importance of financial relief and nutritional benefits for vulnerable populations during the pandemic.
A study in the JAMA Network Open found that Hispanic and American Indian individuals with breast, colorectal, lung, and prostate cancer were undercaptured in the National Cancer Database, but representation improved over time. Further investigation is needed to understand where these populations seek cancer care.
The IASLC Early Detection & Screening Committee published a perspective outlining key components of LDCT screening regimens. The report emphasizes the need for data-driven management systems, quality assurance assessments, and multi-disciplinary clinical management to maximize benefits of early detection and treatment.
Researchers identified Benidipine as a compound promoting the death of cigarette smoke-induced senescent lung cells, improving lung emphysema. The dihydropyridine family of calcium channel blockers constitutes a new class of senolytics that could improve lung diseases.
A study published in the Journal of Thoracic Oncology found that adopting a lung nodule program can increase early lung cancer detection for patients not eligible for traditional screening. The study revealed significant differences in stage at diagnosis and overall survival rates between young, elderly, and screened cohorts.
A novel inhibitor drug, KRB-456, has been discovered to target the KRAS G12D mutation in pancreatic cancer patient-derived tumors. The study demonstrates that KRB-456 significantly inhibits tumor growth in mice, offering a promising therapeutic option for KRAS-driven cancers.
Researchers have discovered that immune cells play a crucial role in directing the growth of human lung tissue during development, revolutionizing our understanding of early lung development. The findings also suggest that early immune disturbances could manifest as pediatric lung disease.
Researchers at Johns Hopkins Medicine used liquid biopsies to monitor changes in circulating tumor DNA and detect immune cell expansions, predicting patient responses to immunotherapies and detecting early signs of toxic side effects. The test showed significant associations with progression-free and overall survival.
A recent study published in JNCCN found that patients from underrepresented groups treated with first-line immunotherapy for advanced Non-Small Cell Lung Cancer (NSCLC) showed similar survival outcomes as their White counterparts. The study analyzed data from 248 patients and highlighted the need for more diverse patient representation...
New research found that less than five minutes of daily physical activity can be beneficial for people living with inoperable lung cancer, reducing mortality rates by 60% compared to those who were largely inactive. Healthcare providers should investigate a person's levels of physical activity in early management of the disease.
Researchers identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer. Combining immunotherapy with dupilumab boosted patients' immune systems and showed significant tumor reduction in six out of six cases.
Researchers Haval Shirwan and Esma Yolcu design a molecule, SA-4-1BBL, that mobilizes immune cells to target cancer cells. The molecule shows promising results in preventing lung cancer by triggering the immune system's defense mechanism.
The Lung-MAP trial has demonstrated the potential of public-private partnerships in clinical research, increasing access to new treatment options for patients with lung cancer. The unique partnership between academia, advocacy, federal agencies, and industry has led to a more representative patient group being enrolled in clinical trials.
A new study finds that structural racism is a significant contributor to unequal lung cancer risk factors, affecting different racial and ethnic groups differently. The research highlights the need for tailored preventive interventions to address these disparities.
A systematic review of papers found abnormalities in brain cancer and potential treatment with licensed drugs. Genetic differences were discovered between smokers and non-smokers, suggesting personalized medicine approaches.
A new study by Tulane University has identified a previously unknown molecular pathway that could halt lung cancer growth. The research found that protein RBM10 can suppress lung cancer by targeting the function of c-Myc, a protein that drives cancer cell growth and proliferation.
Researchers developed an AI tool that can identify never-smokers at high risk for lung cancer based on their chest X-ray images. The study found that 28% of non-smokers were deemed high risk by the model, and these patients had a 2.1 times greater risk of developing lung cancer compared to low-risk individuals.
A phase 2 trial found that durvalumab is safe and may benefit overall survival in non-small cell lung cancer patients with borderline performance status. The study also showed stable quality of life and a lower incidence of severe treatment-related adverse events compared to platinum doublet chemotherapy.
Researchers at Memorial Sloan Kettering Cancer Center have found that lung cancer cells retain a 'memory' of their healthy cell counterparts, which could be exploited to improve treatment with KRAS inhibitors. Eliminating these AT1-like cells improves treatment response to the drugs.
The November issue of CHEST journal features cutting-edge research on asthma, COPD, diffuse lung disease, and thoracic oncology. A new guideline provides updated recommendations for patients with stable COPD, while home spirometry is shown to be less consistent than clinic spirometry in monitoring lung function in patients with asthma.
A new study funded by Cancer Research UK reveals that smoking tobacco causes 20.8 million years of life loss each year, with four preventable risk factors contributing to over 30 million years of life lost annually. The study suggests that action on a global scale could save millions of lives from preventable cancers.
A University of Adelaide and Oxford University study found that asbestos exposure led to a higher incidence of lung cancers in British and Australian naval personnel compared to other armed forces. The researchers estimated that 27% of lung cancers in Australian seamen were related to onboard asbestos exposure.
A new study suggests that analyzing genetic material from nearby healthy tissue may help predict lung cancer's return after treatment. The study analyzed RNA from tumor cells and adjacent, seemingly normal lung tissue and found that the expression of genes associated with inflammation was especially useful for making predictions.
Researchers identified a mechanism that fuels cancer cell growth and developed a new strategy to restrict this process. By restricting glucose in lung cancer cells, they found it caused the cells to lose their specialized features, making them more aggressive.
A large-scale study found that low-dose CT screening increases the 20-year survival rate of lung cancer patients from 18.6% to 81%, with Stage I cancers having an even higher long-term survival rate of 95%. Early detection through annual screening can effectively cure lung cancer in the long term.
A new study published in Radiology shows that patients diagnosed with lung cancer via CT screening have a 20-year survival rate of 81 percent, significantly higher than the average five-year survival rate for all lung cancer patients. Early detection through routine screening can lead to a cure if found early.
Men who are overweight or obese at age 18 have a higher risk of developing 17 different cancers later in life. Higher BMI is also associated with an increased risk of mortality after cancer diagnosis for certain types of cancer.
Researchers at Mainz University Medical Center aim to improve patients' quality of life by applying smart data technology to physical activity. The DECIDE project aims to provide individualized control of patients' daily physical activity, while the RELEVIUM project focuses on alleviating pain and weight loss in pancreatic cancer patie...
The updated guideline recommends yearly low-dose CT scan screening for people aged 50-80 years old with a 20+ pack-year history of smoking. This expansion aims to detect lung cancer early, potentially saving lives.
Researchers at Duke University developed an innovative antibody approach to target and kill tumor-promoting molecules found in cancer cells. The study revealed notable reductions in tumor growth and minimal side effects, making it a promising new treatment option for various types of cancer.
A recent study led by Stanford Medicine researchers found that national lung cancer screening guidelines are less effective for African Americans than whites. An alternative risk-based method showed better results in eliminating disparities among races. The disparities persist despite guideline revisions implemented in 2021.
A UCLA-led study shows datopotamab deruxtecan, a Trop-2 directed antibody-drug conjugate, significantly improves progression-free survival in patients with metastatic non-small cell lung cancer. The treatment primarily benefits patients with non-squamous tumors, reducing disease progression and improving overall survival.
Researchers at H. Lee Moffitt Cancer Center & Research Institute demonstrate lorlatinib's activity against protein PYK2 in non-small cell lung cancer cells, revealing a potential path for repurposing the drug for other cancers. The study shows that combination therapy targeting ROS1, PYK2, and SRC results in enhanced cancer cell death ...
A new study reveals a reversal in the trend of early-onset lung cancer, now affecting younger women and middle-aged adults. The increased incidence in women is attributed to rising rates among those born in the 1960s, without higher smoking prevalence.
A multilevel primary care intervention, including electronic health record reminders and patient outreach, improved timely follow-up of overdue abnormal cancer screening test results for breast, cervical, colorectal, and lung cancer. The intervention was found to be effective in reducing missed screenings.
Researchers discovered that the short-chain fatty acid propionate can reduce metastases in mice with experimental lung cancer. The substance also increases the effectiveness of Cisplatin, a commonly used drug for lung cancer patients. Funding is now sought to identify patients who may benefit from propionate treatment.
A phase 2 clinical trial found that serial blood tests can identify patients who benefit from additional immunotherapies, suggesting a potential early marker of treatment response. The study also showed that ctDNA analyses correlated with tumor size and survival, making it a promising strategy for guiding therapy.
A new study found that an alternative model to identify patients with lung cancer eligible for screening was more accurate than the currently used method based on the United States Preventive Services Task Force (USPSTF) criteria. The PLCOm2012 models had higher sensitivity and identified more people with lung cancer eligible for scree...
A new AI tool developed by Brazilian researchers can detect potentially cancerous lung nodules in CT reports, missing a crucial early diagnosis. The NLP tool achieved an accuracy rate of 97% in identifying suspicious nodules.
A machine learning model developed by researchers can predict lung cancer risk with an 83.9% sensitivity, identifying those who need screening for the disease. The model uses just three predictors: age, smoking duration, and pack-years of smoking, making it a simplified approach to determine high-risk populations.
A novel liquid biopsy test identifies levels of circulating tumor DNA as a more precise measure of disease burden than the number of tumors themselves. Patients with lower levels of detectable ctDNA are more likely to benefit from radiation therapy.
Researchers have made significant progress in using immunotherapies prior to surgery, leading to better biomarkers and more effective combination therapies. This approach has shown promise in various cancer types, including lung cancer, triple-negative breast cancer, melanoma, and gastrointestinal cancers.
Cancer cells exploit enhancer DNA to accelerate tumor growth, according to researchers at the University of Toronto. The study found that specific proteins regulate this process, suggesting potential treatments through FOXA1 or NFIB suppression.
A new editorial paper highlights the importance of including older patients in lung cancer clinical trials, where they are often undertreated due to age-related factors. The paper emphasizes the need for increased collaboration among stakeholders to enhance enrollment and retention of older cancer patients.
A Rice University-led team of researchers has been awarded $45 million to develop a new sense-and-respond implant technology that could improve immunotherapy outcomes for patients with difficult-to-treat cancers. The technology, called THOR, aims to provide real-time data from the tumor environment to guide more effective therapies.
The 'Crystal Ribcage' technology enables scientists to study lung function at a cellular level while maintaining physiological processes. This innovation holds immense potential for understanding lung diseases and developing new treatments.
The five-year grant will utilize ecological and evolutionary principles to study non-small cell lung cancer growth and treatment resistance. Researchers aim to uncover novel therapeutic strategies that can suppress the evolution of resistance in this common type of lung cancer.
Researchers developed a scoring system analyzing income, education, geographical location, access to care, and other factors to identify patients at increased risk of poor outcomes. The study found significant socioeconomic disadvantage associated with a 21% decrease in textbook outcomes and a 32% decrease in overall survival.
Researchers have successfully developed a robot that can autonomously navigate through living lung tissue, avoiding vital structures such as airways and blood vessels. This innovation enables surgeons to reach previously inaccessible small tumors, improving treatment outcomes for patients with lung cancer.
Researchers found that beta-blockers can revive exhausted killer T cells, making them better cancer fighters. The study discovered a link between the sympathetic stress response and immune system response to cancer.
Researchers found higher 5-year survival rates among Kaiser Permanente patients compared to National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) estimates. Improved screening rates, cancer treatment pathways, and coordinated care may have contributed to these higher survival rates.
A study by researchers at the University of Miami Miller School of Medicine found that thoracic surgeons who treat lung cancer are helping to reduce patients' risk of opioid dependence. The ERATS protocol, which includes intercostal nerve blocks and safe pain relievers, enables earlier hospital discharge with nearly opioid-free recovery.
A study at the University of Miami Miller School of Medicine found that robot-assisted surgeries and improved pain-management initiatives led to earlier discharges for many patients. However, lower-income patients were less likely to be discharged on day one due to socioeconomic disparities.
The September issue of the CHEST journal features research on long COVID, including a review on exercise pathophysiology in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Postacute Sequelae of SARS-CoV-2. Original studies also explore asthma treatment with albuterol-budesonide inhalers and sleep therapy using oronasal masks.
Researchers at MD Anderson Cancer Center found that combination immunotherapy with durvalumab and novel agents outperforms durvalumab alone in early-stage non-small-cell lung cancer. The study showed higher major pathological response rates for combination therapy, with some regimens inducing up to 31.3% of MPR.